Health
FDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process – FDA.gov
BioFire Diagnostics LLC granted De Novo for its BioFire Respiratory Panel 2.1.
For Immediate Release:
March 17, 2021
Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 and other respiratory tract infections. The diagnostic test, which had an Emergency Use Authorization (EUA), was granted marketing…
-
General11 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News20 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General11 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News15 hours agoBrisbane rising on global rankings, but still behind southern capitals